サンプル依頼リスト カート
  • English
  • Korean
表紙：夜盲症治療の世界市場：2023年～2030年
市場調査レポート
商品コード
1382521

夜盲症治療の世界市場：2023年～2030年

Global Night Blindness Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.40円
夜盲症治療の世界市場：2023年～2030年
出版日: 2023年11月17日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

夜盲症は、先天的、後天的を問わず、多くの疾患によって引き起こされる可能性があります。視界がぼやけることがあり、低照度によって悪化する疾患（白内障、近視、緑内障など）は、真の夜盲症とは区別する必要があります。薄暗い照明環境に目が適応できないことを夜盲症といいます。桿体細胞の問題が夜盲症の最も多い原因ですが、他にも多くの原因があります。

根本的な原因によって、夜盲症の正確な治療方法が決まります。網膜の桿体細胞の老化は、多くの病気によって引き起こされます。夜盲症は病気の別名です。目の痛み、吐き気、かすみ、ハロー、光過敏、遠方視障害、頭痛などがこの病気の症状です。

市場力学：促進要因と阻害要因

近視とビタミンA欠乏症の有病率の上昇

近視とビタミンA欠乏症の増加は、一般的になりつつある2つの症状であり、この市場開拓は市場前進の主な要因となります。例えば、国際近視研究所（The International Myopia Institute）の報告によると、近視の有病率は世界的に上昇しており、主にライフスタイル要因の結果として、2050年までに世界人口の50％に影響が及ぶと予想されています。

緑内障、白内障、網膜剥離など、視力を脅かす障害のリスクも近視と関連しています。さらにWHOは、毎年25万人から50万人のビタミンA欠乏症の子供が失明し、その半数が失明後1年以内に亡くなっていると推定しています。ビタミンA欠乏症は、小児失明の予防可能な最大の原因であり、一般的な小児疾患によるかなりの罹患率と死亡率に関係しています。

ヘルスケア費用の上昇も、夜盲症治療市場の成長率に影響を与える主な要因です。夜盲症治療市場は、医療技術の発展に加え、公的機関だけでなく民間団体による啓発活動の高まりや政府支援の増加によって成長すると思われます。

市場力学：阻害要因

夜盲症の管理には多くの制約があるため、治療の効果が妨げられる可能性があります。例えば、特に手術やその他の専門的な介入による夜盲症の治療には費用がかかるため、十分な経済的余裕のない人や健康保険に加入していない人にとっては、必要な治療を受けることが難しくなる可能性があります。

さらに、夜盲症を効果的に管理・治療するためには、早急な診断が不可欠です。眼科の一部の分野、特に夜盲症の希少な原因や遺伝的な原因に対する広範な研究開発の欠如も、先進的な治療法の利用を制限する可能性があります。また、根本的な原因の特定が遅れると、治療の選択肢が狭まり、介入の効果も低下します。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 近視とビタミンA欠乏症の増加
      • 治療技術の進歩
  • 抑制要因
      • 高額な治療費
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ
  • DMI意見

第6章 COVID-19分析

第7章 治療タイプ別

  • 薬物療法
  • 遺伝子治療
  • その他

第8章 年齢層別

  • 小児
  • 成人

第9章 診断別

  • 血液検査
  • 色覚検査
  • 網膜電図（ERG）
  • その他

第10章 販売チャネル別

  • 販売チャネル
  • エンドユーザー

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Nestle
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • NOWfoods Inc
  • Kirkland Signature
  • Life Extension
  • Garden of Life
  • Nidek, Inc
  • Alcon Laboratories, Inc
  • Carl Zeiss, Inc
  • VISX, Inc
  • Wavelight AG

第14章 付録

目次
Product Code: PH7428

Overview

Night blindness can be caused by many disease processes, both inherited and acquired. Differentials that may cause blurred vision, and that are made worse by low light levels (e.g., cataracts, myopia, glaucoma) should be distinguished from true night blindness. The inability of the eyes to adjust to dim lighting conditions is known as night blindness. Although issues with the rod cells are the most frequent cause of night blindness, there are numerous additional causes as well.

The underlying cause determines the exact procedure for treatment for night blindness. The ageing of the retina's rods is brought on by a number of diseases. Nyctalopia is another name for disease. Eye pain, nausea, blurred vision, halos, light sensitivity, distance vision problem, and headaches are all symptoms of this diseases.

Market Dynamics: Drivers and Restraints

The rising prevalence of myopia and vitamin A deficiency

The rise of myopia and vitamin A deficiency are two conditions that are becoming more common, and this development will be a key factor in the market's advancement. For instance, The International Myopia Institute reported that the prevalence of myopia is rising globally and is expected to impact 50% of the world's population by 2050, primarily as a result of lifestyle factors.

The risk of sight-threatening disorders from glaucoma, cataract, and retinal detachment has also been linked to myopia. Additionally, WHO estimates that every year, between 250,000 and 500,000 children who are vitamin A deficient become blind, and half of them pass away within a year after losing their sight. Vitamin A deficiency is the largest preventable cause of childhood blindness and is related with considerable morbidity and mortality from common childhood illnesses.

The rising cost of healthcare is also a major factor affecting the market's growth rate for treatments for night blindness. The market for night blindness treatments will grow as a result of rising awareness-raising efforts by private as well as public organisations and increasing government support, in addition to developments in medical technology.

Market Dynamics: Restraint

The effectiveness of therapies can be hampered by a number of restraints on the management of night blindness. For instance, the cost of treating night blindness, particularly through surgeries and other specialised interventions, might make it difficult for those without sufficient financial means or health insurance to get the essential care.

Additionally, an immediate diagnosis is essential for managing and treating the condition effectively. Lack of extensive research and development in some areas of ophthalmology, particularly for rare or genetic causes of night blindness, can also limit the availability of advanced treatment options. Delay in identifying the underlying cause can also restrict treatment options and reduce the effectiveness of interventions.

Segment Analysis

The global night blindness treatment marketis segmented based on treatment type, age group, diagnosis, sales channel and region.

The gene therapy segment from the type segment accounted for approximately 40.7% of night blindness treatment share

A promising approach for treating a variety of genetic diseases, such as night blindness caused on by particular genetic abnormalities, is gene therapy. Nyctalopia, often known as night blindness, is frequently linked to gene variations that are crucial for the operation of retinal cells, particularly rod cells, which are responsible for seeing in low light. Researchers create a therapeutic gene that can either enhance the function of the mutant gene or replace the defective gene (gene replacement therapy). This gene is often created to improve the function of photoreceptor cells in the retina to treat night blindness.

For instance, in March 2021, according to Elsevier Inc, a study demonstrates that gene therapy can significantly improve night vision in adult mice with CSNB. Similar to this, some types of CSNB can be cured by using a special type of gene therapy that targets the nerve cells in the retina. While there is presently no treatment for CSNB, recent developments in gene therapy provide opportunity. Adaptations to enhance general quality of life and night vision are frequently necessary for managing this disease.

Geographical Analysis

North America accounted for approximately 36.4% of the market share in 2022

Due to the existence of significant key players, high disposable income, and well-established healthcare infrastructure in North America, this region dominates the market for night blindness treatments. Additionally, the prevalence of diabetes, glaucoma, and cataract will rise, along with increased attempts by governmental and commercial organisations to raise awareness. These factors will lead to an expansion of the night blindness treatment market in the region.

For instance, according to Diabetes Research Institute Foundation, around 37.3 million people, or 11.3% of the U.S. population, have diabetes. An estimated 29 million people - had diagnosed diabetes. Approximately 8.5 million people have diabetes but have not yet been diagnosed.

Additionally, according to BrightFocus Foundation 2023, more than 3 million Americans are living with glaucoma, 2.7 million of whom (aged 40 and older) are affected by its most common form, open-angle glaucoma. Thus, above factors accelerate the region growth.

COVID-19 Impact Analysis

Many non-emergency medical services, such as some eye care procedures and elective operations, were postponed or cancelled during the peak of the epidemic in order to prioritize resources for COVID-19 patients. Treatments for night blindness may not have been as readily available because of this complication. Hospitals and healthcare facilities may need to give COVID-19 patients priority, which could cause delays for less urgent treatments, such as some ophthalmology-related procedures.

The scheduling and accessibility of operations linked to night blindness may be impacted by this reprioritization. The pandemic's economic effects, which include job losses and decreased income for many people, may make it more difficult for them to pay for healthcare services, including treatments for night blindness. Medical operations that are not absolutely necessary may be postponed or avoided due to financial restrictions.

Market Segmentation

By Treatment Type

  • Medication
  • Gene Therapy
  • Others

By Age Group

  • Pediatric
  • Adult

By Diagnosis

  • Blood tests
  • Color vision testing
  • Electroretinogram (ERG)
  • Others

By Sales Channel

  • Distribution Channel
  • End User

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the market include: Nestle, NOWfoods Inc, Kirkland Signature, Life Extension, Garden of Life, Nidek, Inc, Alcon Laboratories, Inc, Carl Zeiss, Inc, VISX, Inc, Wavelight AG and among others.

Key Developments

  • On July 21, 2022, by increasing its global formulation capabilities at its Verbund plant in Ludwigshafen, BASF is enhancing its market position in the vitamin A market. The innovative facility, which is fully integrated into vitamin production at the location, will support and increase the manufacture of high-quality vitamin A powder products for the animal nutrition industry.
  • On August 07, 2023, HuidaGene, in preclinical research, its gene therapy candidate exceeded FDA-approved Luxturna. One-time gene replacement therapy called HG004 by China-based HuidaGene, which was granted orphan drug status in March 2023, is designed to treat people with inherited retinal diseases (IRDs) brought on by mutations in the RPE65 gene.

Why Purchase the Report?

  • To visualize the global night blindness treatment market segmentation based on treatment type, age group, diagnosis, sales channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of night blindness treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global night blindness treatment market report would provide approximately 69 tables, 66 figures and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by Diagnosis
  • 3.4. Snippet by Sales Channel
  • 3.5. Snippet by Region

4. Market Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising prevalence of myopia and vitamin A deficiency
      • 4.1.1.2. Technological advancements of the treatment
  • 4.2. Restraints
      • 4.2.1.1. Expensive cost associated with the treatment
    • 4.2.2. Opportunity
    • 4.2.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Medication *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Gene Therapy
  • 7.4. Others

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Pediatric *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Adult

9. By Diagnosis

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 9.1.2. Market Attractiveness Index, By Diagnosis
  • 9.2. Blood tests *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Color vision testing
  • 9.4. Electroretinogram (ERG)
  • 9.5. Others

10. By Sales Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.1.2. Market Attractiveness Index, By Sales Channel
  • 10.2. Distribution Channel *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. End User

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Nestle *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. NOWfoods Inc
  • 13.3. Kirkland Signature
  • 13.4. Life Extension
  • 13.5. Garden of Life
  • 13.6. Nidek, Inc
  • 13.7. Alcon Laboratories, Inc
  • 13.8. Carl Zeiss, Inc
  • 13.9. VISX, Inc
  • 13.10. Wavelight AG

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us